13F Holdings
中文EN

IONS IONIS PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 874015 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-0.7%
TTM net income YoY-113.2%
TTM EPS YoY-96.4%
Revenue 3-yr CAGR16.0%
Net income 3-yr CAGR—

Margins

Gross margin98.2%
Operating margin-58.8%
Net margin-56.9%
FCF margin-64.2%
EBITDA margin-57.4%

Returns

ROE-108.1%
ROA-18.4%
ROIC (approx.)-236.8%
Asset turnover0.32x

Leverage & solvency

Liabilities / assets86.5%
Debt / equity0.00x
Current ratio5.43x
Interest coverage-29.37x

Cash quality & payout

Operating cash flow / net income1.00x
Accruals ratio-0.1%
Payout ratio—
Capex / revenue7.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q42025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q42024-12-31
Income statement
Revenue$242.72M$267.95M$246.09M$203.33M$156.72M$452.05M$131.61M$226.58M
Cost of revenue$3.32M$2.74M$2.98M$7.96M$2.34M$4.15M$1.46M$3.83M
Gross profit$239.40M$265.21M$243.11M$195.37M$154.38M$447.90M$130.15M$222.75M
SG&A expense$154.22M$150.40M$150.36M$130.19M$96.81M$90.62M$76.25M$88.08M
Operating income-$130.70M-$102.29M-$117.42M-$214.46M-$160.18M$139.82M-$146.86M-$110.82M
Interest expense$4.63M$4.62M$5.16M$4.83M$4.21M$4.11M$4.11M$4.19M
Pretax income-$110.11M-$113.38M-$92.31M-$227.92M-$128.39M$123.53M-$146.82M-$107.04M
Income tax-$141,000$1.26M$218,000$1.48M$213,000-$20,000$116,000-$2.69M
Net income-$109.97M-$114.65M-$92.53M-$229.39M-$128.61M$123.55M-$146.94M-$104.35M
EBITDA-$127.10M-$98.86M-$114.12M-$211.20M-$157.93M$142.08M-$144.63M-$108.58M
EPS (basic)-0.66-0.69-0.56-1.41-0.800.78-0.93-0.66
EPS (diluted)-0.66-0.69-0.56-1.41-0.800.70-0.93-0.66
Weighted avg. shares (diluted)166.21M165.42M164.87M—159.76M182.33M158.74M—
Balance sheet
Cash & equivalents$296.30M$350.06M$173.38M$372.26M$338.34M$297.30M$264.19M$242.08M
Short-term investments$1.59B$1.70B$1.75B$2.31B$1.90B$1.99B$1.88B$2.06B
Inventory$28.58M$50.83M$5.56M$10.05M$10.47M$8.48M$11.50M$12.51M
Current assets$2.36B$2.49B$2.94B$2.99B$2.52B$2.58B$2.42B$2.62B
PP&E, net$162.06M$155.13M$142.40M$123.05M$106.12M$111.95M$102.92M$94.25M
Total assets$2.91B$2.99B$3.45B$3.52B$3.03B$2.99B$2.81B$3.00B
Current liabilities$435.29M$315.64M$716.59M$781.57M$903.46M$897.24M$250.29M$309.32M
Short-term debt———$432.12M———$165,000
Long-term debt———$1.33B———$1.20B
Total debt———$1.76B———$1.20B
Total liabilities$2.52B$2.55B$2.96B$3.03B$2.42B$2.35B$2.34B$2.42B
Shareholders' equity$393.64M$439.74M$491.41M$489.09M$617.97M$631.72M$475.73M$588.35M
Net debt———$1.39B———$960.49M
Shares outstanding166.41M165.64M165.90M163.30M161.14M159.20M159.04M157.91M
Cash flow statement
Operating cash flow-$179.42M$565.53M-$792.82M-$137.71M-$131.44M$151.34M-$150.78M-$116.14M
Capital expenditure$12.71M$16.08M$21.76M$21.29M$5.27M$12.30M$12.58M$25.50M
Free cash flow-$192.13M$549.45M-$814.58M-$159.00M-$136.71M$139.03M-$163.35M-$141.64M
Investing cash flow$99.88M$23.50M$536.82M-$419.50M$91.34M-$120.07M$170.46M$68.21M
Financing cash flow$25.79M-$412.29M$57.26M$591.18M$81.22M$1.25M$2.20M-$44.12M
Depreciation & amortization$3.60M$3.43M$3.30M$3.26M$2.25M$2.27M$2.23M$2.24M
Stock-based compensation$43.42M$45.59M$43.27M$43.32M$31.15M$29.69M$29.72M$36.15M

Free plan shows the latest 8 periods; Pro shows all 70 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.